Long-term Clinical Study Of Sorafenib For Advanced Renal Cell Carcinoma：Report Of25Cases

Objective: To evaluate the efficacy and safety in the Long-termtreatment of advanced renal cell carcinoma (RCC) with sorafenib, andinvestigate the survival time for patients with RCC. Method: We reviewedthe clinical date of25patients with advanced RCC from February2008toSeptember2013.Tumor control, long-term survival and theoccurrence, level, and prognosis of adverse effects patients were recorded.Result: According to6-59months’ follow up with25advanced RCCpatients, which the medium month was23.8(17-30months, CI95%). Allpatients were evaluable for response and toxicity，with1cases (4％)ofcomplete response，9cases (36％)of partial response，10cases (40％)ofstable disease，and5cases(20％)of disease progression．The disease controlrate(DCR) was80％，the median progression free survival(PFS) time andthe median overall survival was14months（CI95%;3~24）and36months（CI95%;13~59）. Common adverse include hypertension (48%), anemia(36%), fatigue (44%), diarrhea (40%), rash (40%) and PPE (56%).Relatively rare adverse include weight loss, nausea, loss of appetite, pain and alopecia.. The relatively rare adverse effects included weight loss,nausea, anorexia, pain, and hair loss, etc. It appeared in week1-8, whichthe medium adverse effect period appeared in week3(2.0–3.5, CI95%).The adverse effect of76%patients partly relieved or disappeared aftersymptomatic treatment. The median relieving period was week20(14.1-25.5，CI95%).20%patients got relatively mild adverse reaction.4%patients get relatively severe adverse reaction. The adverse effect relievedafter reducing medicine dose.The OS and PFS of the patients with hypertension weresignificantly shorter than whom did not suffer from hypertension（p＜0.05）.Conclusion: Sorafenib has obvious inhibiting effect for tumour progressionof metastatic RCC. Patients taking standard doses,after taking increaseddoses,could still have a relatively long progression free survival period.Theadverse effect appears at early period, and most adverse effects areacceptable in long-term medicating for patient. Of adverse effect,hypertension might have a predictive effect o survival period of patients.